nach oben

Cancer Chemotherapy and Pharmacology

Erschienen in:

06.05.2016 | Original Article

Predictive value of GSTP1 Ile105Val polymorphism in clinical outcomes of chemotherapy in gastric and colorectal cancers: a systematic review and meta-analysis

verfasst von: Xiaobing Shen, Jia Wang, Xiaoluan Yan, Xiaofeng Ren, Fan Wang, Xiaowei Chen, Yuchao Xu

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Gastric and colorectal cancers remain the major causes of cancer-related death with a bad prognosis. Up to now, platinum combined with fluoropyrimidines has been most commonly used in chemotherapy regimens of gastric and colorectal cancers. Recently, a series of studies have been conducted to investigate the associations of biomarkers, such as GSTP1 Ile105Val polymorphism, with the chemotherapy efficacy in gastric and colorectal cancers; however, the results were not consistent and inconclusive. Here, we performed a systematic review and meta-analysis to summarize the associations of GSTP1 Ile105Val polymorphism with the chemotherapy efficacy in gastric and colorectal cancers.

Methods

A systematic review was conducted to search relevant studies in English databases (PubMed, ISI Web of Science, and EMBASE) up to November 30, 2015. The pooling ORs or HRs were used to assess the strength of the associations of GSTP1 Ile105Val polymorphism with clinical outcomes such as tumor response, toxicity, progression-free survival (PFS), and overall survival (OS).

Results

Forty-one papers containing 8169 cases were finally included in the present meta-analysis study. Of which, 28 articles were performed in colorectal cancers, one in gastrointestinal carcinoma (gastric and colon cancer), 11 in gastric cancers, and one in colorectal and gastroesophageal cancers. After pooling all the eligible studies, we identified significant associations of GSTP1 Ile105Val polymorphism with chemotherapy-related tumor response (G vs. A: OR 1.697, 95 % CI 1.191–2.418; GG vs. AA: OR 2.804, 95 % CI 1.414–5.560; AG vs. AA: OR 1.540, 95 % CI 1.011–2.347; GG vs. AAAG: OR 2.139, 95 % CI 1.256–3.641), PFS (GG vs. AA, HR 0.640, 95 % CI 0.455–0.900; AGGG vs. AA: HR 0.718, 95 % CI 0.562–0.919), and OS (AG vs. AA: HR 0.857, 95 % CI 0.746–0.986; GG vs. AA: HR 0.679, 95 % CI 0.523–0.882; AGGG vs. AA: HR 0.663, 95 % CI 0.542–0.812) in gastric and colorectal cancers and no significant association was found between the polymorphism with toxicity.

Conclusions

GSTP1 Ile105Val polymorphism was associated with tumor response, PFS, and OS in gastric and colorectal cancers after chemotherapy.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58(2):71–96. doi:10.3322/CA.2007.0010 CrossRefPubMed

Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64(1):9–29. doi:10.3322/caac.21208 CrossRefPubMed

Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24(14):2137–2150. doi:10.1200/JCO.2005.05.2308 CrossRefPubMed

Macdonald JS (2004) Treatment of localized gastric cancer. Semin Oncol 31(4):566–573CrossRefPubMed

Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE (2006) Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24(18):2903–2909. doi:10.1200/JCO.2005.05.0245 CrossRefPubMed

Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, Fleig WE (2010) Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev (3):CD004064. doi:10.1002/14651858.CD004064.pub3

Wohrer SS, Raderer M, Hejna M (2004) Palliative chemotherapy for advanced gastric cancer. Ann Oncol 15(11):1585–1595. doi:10.1093/annonc/mdh422 CrossRefPubMed

Xu R, Ma N, Wang F, Ma L, Chen R, Chen R, Kebinu M, Ma L, Han Z, Ayixiamu MM, Su P, Naman Y, Jieensi H, Yang H, Adili A, Aili S, Liu J (2013) Results of a randomized and controlled clinical trial evaluating the efficacy and safety of combination therapy with Endostar and S-1 combined with oxaliplatin in advanced gastric cancer. OncoTargets Ther 6:925–929. doi:10.2147/OTT.S46487

Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirzen F, Noh SH, Investigators Ct (2012) Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379(9813):315–321. doi:10.1016/S0140-6736(11)61873-4 CrossRefPubMed

10.

Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Rittweger K, Gilberg F, Saltz L (2011) XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer 105(1):58–64. doi:10.1038/bjc.2011.201 CrossRefPubMedPubMedCentral

11.

Chua W, Kho PS, Moore MM, Charles KA, Clarke SJ (2011) Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer. Crit Rev Oncol Hematol 79(3):224–250. doi:10.1016/j.critrevonc.2010.07.012 CrossRefPubMed

12.

Cortejoso L, Lopez-Fernandez LA (2012) Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients. Pharmacogenomics 13(10):1173–1191. doi:10.2217/pgs.12.95 CrossRefPubMed

13.

Goekkurt E, Hoehn S, Wolschke C, Wittmer C, Stueber C, Hossfeld DK, Stoehlmacher J (2006) Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)—novel predictors for response and survival in gastric cancer patients. Br J Cancer 94(2):281–286. doi:10.1038/sj.bjc.6602891 CrossRefPubMedPubMedCentral

14.

Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH, Pommier Y (2002) Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 62(17):4899–4902PubMed

15.

Sohn KJ, Croxford R, Yates Z, Lucock M, Kim YI (2004) Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst 96(2):134–144CrossRefPubMed

16.

Peklak-Scott C, Smitherman PK, Townsend AJ, Morrow CS (2008) Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin. Mol Cancer Ther 7(10):3247–3255. doi:10.1158/1535-7163.MCT-08-0250 CrossRefPubMedPubMedCentral

17.

Karam RA, Pasha HF, El-Shal AS, Rahman HM, Gad DM (2012) Impact of glutathione-S-transferase gene polymorphisms on enzyme activity, lung function and bronchial asthma susceptibility in Egyptian children. Gene 497(2):314–319. doi:10.1016/j.gene.2012.01.059 CrossRefPubMed

18.

Wang Y, Zeng T (2013) Response to: Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 14:391. doi:10.1186/1745-6215-14-391 CrossRefPubMedPubMedCentral

19.

Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16. doi:10.1186/1745-6215-8-16 CrossRefPubMedPubMedCentral

20.

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188CrossRefPubMed

21.

Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088–1101CrossRefPubMed

22.

Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634CrossRefPubMedPubMedCentral

23.

Stoehlmacher J, Park DJ, Zhang W, Groshen S, Tsao-Wei DD, Yu MC, Lenz HJ (2002) Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 94(12):936–942CrossRefPubMed

24.

Lecomte T, Landi B, Beaune P, Laurent-Puig P, Loriot MA (2006) Glutathione S-transferase P1 polymorphism (Ile(105)Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 12(10):3050–3056. doi:10.1158/1078-0432.ccr-05-2076 CrossRefPubMed

25.

Ruzzo A, Graziano F, Kawakami K, Watanabe G, Santini D, Catalano V, Bisonni R, Canestrari E, Ficarelli R, Menichetti ET, Mari D, Testa E, Silva R, Vincenzi B, Giordani P, Cascinu S, Giustini L, Tonini G, Magnani M (2006) Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J Clin Oncol 24(12):1883–1891. doi:10.1200/jco.2005.04.8322 CrossRefPubMed

26.

Gamelin L, Capitain O, Morel A, Dumont A, Traore S, Anne LB, Gilles S, Boisdron-Celle M, Gamelin E (2007) Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway. Clin Cancer Res 13(21):6359–6368CrossRefPubMed

27.

Le Morvan V, Smith D, Laurand A, Brouste V, Bellott R, Soubeyran I, Mathoulin-Pelissier S, Robert J (2007) Determination of ERCC2 Lys751G1n and GSTP1Ile105Va1 gene polymorphisms in colorectal cancer patients: relationships with treatment outcome. Pharmacogenomics 8(12):1693–1703CrossRefPubMed

28.

Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, Catalano V, Ficarelli R, Maltese P, Bisonni R, Masi G, Schiavon G, Giordani P, Giustini L, Falcone A, Tonini G, Silva R, Mattioli R, Floriani I, Magnani M (2007) Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 25(10):1247–1254. doi:10.1200/jco.2006.08.1844 CrossRefPubMed

29.

Keam B, Im SA, Han SW, Ham HS, Kim MA, Oh DY, Lee SH, Kim JH, Kim DW, Kim TY, Heo DS, Kim WH, Bang YJ (2008) Modified FOLFOX-6 chemotherapy in advanced gastric cancer: results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. BMC Cancer 8:148. doi:10.1186/1471-2407-8-148 CrossRefPubMedPubMedCentral

30.

Kweekel DM, Koopman M, Antonini NF, Van der Straaten T, Nortier JW, Gelderblom H, Punt CJ, Guchelaar HJ (2008) GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group. Br J Cancer 99(8):1316–1321. doi:10.1038/sj.bjc.6604654 CrossRefPubMedPubMedCentral

31.

Ott K, Lordick F, Becker K, Ulm K, Siewert JR, Höfler H, Keller G (2008) Glutathione-S -transferase P1, T1 and M1 genetic polymorphisms in neoadjuvant-treated locally advanced gastric cancer: GSTM1-present genotype is associated with better prognosis in completely resected patients. Int J Colorectal Dis 23(8):773–782CrossRefPubMed

32.

Pare L, Marcuello E, Altes A, del Rio E, Sedano L, Salazar J, Cortes A, Barnadas A, Baiget M (2008) Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. Br J Cancer 99(7):1050–1055. doi:10.1038/sj.bjc.6604671 CrossRefPubMedPubMedCentral

33.

Braun MS, Richman SD, Thompson L, Daly CL, Meade AM, Adlard JW, Allan JM, Parmar MK, Quirke P, Seymour MT (2009) Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. J Clin Oncol 27(33):5519–5528. doi:10.1200/jco.2008.21.6283 CrossRefPubMed

34.

Goekkurt E, Al-Batran SE, Hartmann JT, Mogck U, Schuch G, Kramer M, Jaeger E, Bokemeyer C, Ehninger G, Stoehlmacher J (2009) Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie. J Clin Oncol 27(17):2863–2873. doi:10.1200/JCO.2008.19.1718 CrossRefPubMed

35.

Huang ZH, Hua D, Du X (2009) Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy. Cancer Chemother Pharmacol 64(5):1001–1007. doi:10.1007/s00280-009-0956-2 CrossRefPubMed

36.

Kweekel DM, Gelderblom H, Antonini NF, Van der Straaten T, Nortier JW, Punt CJ, Guchelaar HJ (2009) Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients. Eur J Cancer (Oxf Engl 1990) 45(4):572–578. doi:10.1016/j.ejca.2008.10.015 CrossRef

37.

Liang J, Zhang H, Yin B (2009) Genetic polymorphisms of GSTP1 related to response to 5-FU-oxaliplatin- based chemotherapy and clinical outcome in advanced colorectal cancer patients. Swiss Med Wkly 139(49–50):724–728

38.

Seo BG, Kwon HC, Oh SY, Lee S, Kim SG, Kim SH, Han H, Kim HJ (2009) Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI. Oncol Rep 22(1):127–136PubMed

39.

Boige V, Mendiboure J, Pignon JP, Loriot MA, Castaing M, Barrois M, Malka D, Tregouet DA, Bouche O, Le Corre D, Miran I, Mulot C, Ducreux M, Beaune P, Laurent-Puig P (2010) Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000–2005. J Clin Oncol 28(15):2556–2564. doi:10.1200/JCO.2009.25.2106 CrossRefPubMed

40.

Chen YC, Tzeng CH, Chen PM, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Wang WS (2010) Influence of GSTP1 I105 V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Sci 101(2):530–535CrossRefPubMed

41.

Etienne-Grimaldi MC, Milano G, Maindrault-Goebel F, Chibaudel B, Formento JL, Francoual M, Lledo G, Andre T, Mabro M, Mineur L, Flesch M, Carola E, de Gramont A (2010) Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. Br J Clin Pharmacol 69(1):58–66. doi:10.1111/j.1365-2125.2009.03556.x CrossRefPubMedPubMedCentral

42.

Funke S, Timofeeva M, Risch A, Hoffmeister M, Stegmaier C, Seiler CM, Brenner H, Chang-Claude J (2010) Genetic polymorphisms in GST genes and survival of colorectal cancer patients treated with chemotherapy. Pharmacogenomics 11(1):33–41. doi:10.2217/pgs.09.132 CrossRefPubMed

43.

Inada M, Sato M, Morita S, Kitagawa K, Kawada K, Mitsuma A, Sawaki M, Fujita K, Ando Y (2010) Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes. Int J Clin Pharmacol Ther 48(11):729–734CrossRefPubMed

44.

Kanai M, Yoshioka A, Tanaka S, Nagayama S, Matsumoto S, Nishimura T, Niimi M, Teramukai S, Takahashi R, Mori Y, Kitano T, Ishiguroa H, Yanagihara K, Chiba T, Fukushima M, Matsuda F (2010) Associations between glutathione S-transferase pi Ile(105)Val and glyoxylate aminotransferase Pro(11)Leu and Ile(340)Met polymorphisms and early-onset oxaliplatin-induced neuropathy. Cancer Epidemiol 34(2):189–193. doi:10.1016/j.canep.2010.02.008 CrossRefPubMed

45.

Li Q-F, Yao R-Y, K-w L, Lv H-Y, Jiang T, Liang J (2010) Genetic Polymorphism of GSTP1: prediction of Clinical Outcome to Oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer. J Korean Med Sci 25(6):846–852. doi:10.3346/jkms.2010.25.6.846 CrossRefPubMedPubMedCentral

46.

McLeod HL, Sargent DJ, Marsh S, Green EM, King CR, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Thibodeau SN, Grothey A, Morton RF, Goldberg RM (2010) Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol 28(20):3227–3233. doi:10.1200/JCO.2009.21.7943 CrossRefPubMedPubMedCentral

47.

Shim HJ, Yun JY, Hwang JE, Bae WK, Cho SH, Lee JH, Kim HN, Shin MH, Kweon SS, Lee JH, Kim HJ, Chung IJ (2010) BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin. Cancer Sci 101(5):1247–1254. doi:10.1111/j.1349-7006.2010.01514.x CrossRefPubMed

48.

Zarate R, Rodriguez J, Bandres E, Patino-Garcia A, Ponz-Sarvise M, Viudez A, Ramirez N, Bitarte N, Chopitea A, Gacia-Foncillas J (2010) Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis. Br J Cancer 102(6):987–994. doi:10.1038/sj.bjc.6605595 CrossRefPubMedPubMedCentral

49.

Hong J, Han S-W, Ham HS, Kim T-Y, Choi IS, Kim B-S, Oh D-Y, Im S-A, Kang GH, Bang Y-J, Kim T-Y (2011) Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis. Cancer Chemother Pharmacol 67(6):1323–1331. doi:10.1007/s00280-010-1425-7 CrossRefPubMed

50.

Huang MY, Huang ML, Chen MJ, Lu CY, Chen CF, Tsai PC, Chuang SC, Hou MF, Lin SR, Wang JY (2011) Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy. Pharmacogenet Genomics 21(1):18–25. doi:10.1097/FPC.0b013e3283415124 CrossRefPubMed

51.

Lamas MJ, Duran G, Balboa E, Bernardez B, Touris M, Vidal Y, Gallardo E, Lopez R, Carracedo A, Barros F (2011) Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer. Pharmacogenomics 12(3):433–442. doi:10.2217/pgs.10.196 CrossRefPubMed

52.

Li HY, Ge X, Huang GM, Li KY, Zhao JQ, Yu XM, Bi WS, Wang YL (2012) GSTP1, ERCC1 and ERCC2 polymorphisms, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in colorectal cancer in Chinese population. Asian Pac J Cancer Prev 13(7):3465–3469CrossRefPubMed

53.

Cecchin E, D’Andrea M, Lonardi S, Zanusso C, Pella N, Errante D, De Mattia E, Polesel J, Innocenti F, Toffoli G (2013) A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen. Pharmacogenomics J 13(5):403–409. doi:10.1038/tpj.2012.31 CrossRefPubMed

54.

Ji M, Xu B, Jiang J-T, Wu J, Li X-D, Zhao W-Q, Zhang H-Y, Zhou W-J, Wu C-P (2013) Relationship between Glutathione S-transferase P1 (GSTP1), X-Ray Repair Cross Complementing Group 1 (XRCC1) and 5,10-methylenetetrahydrofolate Reductase (5,10-MTHFR) Gene Polymorphisms and Response to Chemotherapy in Advanced Gastric Cancer. Onkologie 36(6):335–340. doi:10.1159/000351260 CrossRefPubMed

55.

Kumamoto K, Ishibashi K, Okada N, Tajima Y, Kuwabara K, Kumagai Y, Baba H, Haga N, Ishida H (2013) Polymorphisms of GSTP1, ERCC2 and TS-3′UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patients. Oncol Lett 6(3):648–654PubMedPubMedCentral

56.

Lai C-Y, Hsieh L-L, Sung F-C, Tang R, Bai C-H, Wu F-Y, Chiou H-Y, Yeh C-C (2013) Tumor site- and stage-specific associations between allelic variants of glutathione S-transferase and DNA-repair genes and overall survival in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. PLoS ONE. doi:10.1371/journal.pone.0069039

57.

Liu YP, Ling Y, Qi QF, Zhang YP, Zhang CS, Zhu CT, Wang MH, Pan YD (2013) Genetic polymorphisms of ERCC1-118, XRCC1-399 and GSTP1-105 are associated with the clinical outcome of gastric cancer patients receiving oxaliplatin-based adjuvant chemotherapy. Mol Med Rep 7(6):1904–1911PubMed

58.

Nishina T, Takano Y, Denda T, Yasui H, Takeda K, Ura T, Esaki T, Okuyama Y, Kondo K, Takahashi Y, Sugiyama Y, Muro K (2013) A phase II clinical study of mFOLFOX6 plus bevacizumab as first-line therapy for Japanese advanced/recurrent colorectal cancer patients. Jpn J Clin Oncol 43(11):1080–1086. doi:10.1093/jjco/hyt127 CrossRefPubMedPubMedCentral

59.

Kap EJ, Richter S, Rudolph A, Jansen L, Ulrich A, Hoffmeister M, Ulrich CM, Brenner H, Chang-Claude J (2014) Genetic variants in the glutathione S-transferase genes and survival in colorectal cancer patients after chemotherapy and differences according to treatment with oxaliplatin. Pharmacogenet Genomics 24(7):340–347. doi:10.1097/fpc.0000000000000059 CrossRefPubMed

60.

Ruzzo A, Graziano F, Galli F, Giacomini E, Floriani I, Galli F, Rulli E, Lonardi S, Ronzoni M, Massidda B, Zagonel V, Pella N, Mucciarini C, Labianca R, Ionta MT, Veltri E, Sozzi P, Barni S, Ricci V, Foltran L, Nicolini M, Biondi E, Bramati A, Turci D, Lazzarelli S, Verusio C, Bergamo F, Sobrero A, Frontini L, Magnani M (2014) Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients. Sci Rep 4:6828. doi:10.1038/srep06828 CrossRefPubMedPubMedCentral

61.

Joerger M, Huitema ADR, Boot H, Cats A, Doodeman VD, Smits PHM, Vainchtein L, Rosing H, Meijerman I, Zueger M, Meulendijks D, Cerny TD, Beijnen JH, Schellens JHM (2015) Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. Cancer Chemother Pharmacol 75(4):763–772. doi:10.1007/s00280-015-2698-7 CrossRefPubMed

62.

Xu Z, Chen Y, Gu D, Lee NP, Sun S, Gong W, Tan Y, Luk JM, Chen J (2015) SOD2 rs4880 CT/CC genotype predicts poor survival for Chinese gastric cancer patients received platinum and fluorouracil based adjuvant chemotherapy. Am J Transl Res 7(2):401–410PubMedPubMedCentral

63.

Yin M, Yan J, Martinez-Balibrea E, Graziano F, Lenz HJ, Kim HJ, Robert J, Im SA, Wang WS, Etienne-Grimaldi MC, Wei Q (2011) ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. Clin Cancer Res 17(6):1632–1640. doi:10.1158/1078-0432.ccr-10-2169 CrossRefPubMedPubMedCentral

64.

Ma SC, Zhao Y, Zhang T, Ling XL, Zhao D (2015) Association between the ERCC1 rs11615 polymorphism and clinical outcomes of oxaliplatin-based chemotherapies in gastrointestinal cancer: a meta-analysis. OncoTargets Ther 8:641–648. doi:10.2147/ott.s80913

65.

Liu X, Cheng D, Kuang Q, Liu G, Xu W (2013) Association between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in Caucasians. PLoS One 8(3):e58489. doi:10.1371/journal.pone.0058489 CrossRefPubMedPubMedCentral

66.

Liu X, Cheng D, Kuang Q, Liu G, Xu W (2014) Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians. Pharmacogenomics J 14(2):120–129. doi:10.1038/tpj.2013.10 CrossRefPubMedPubMedCentral

67.

Rosmarin D, Palles C, Church D, Domingo E, Jones A, Johnstone E, Wang H, Love S, Julier P, Scudder C, Nicholson G, Gonzalez-Neira A, Martin M, Sargent D, Green E, McLeod H, Zanger UM, Schwab M, Braun M, Seymour M, Thompson L, Lacas B, Boige V, Ribelles N, Afzal S, Enghusen H, Jensen SA, Etienne-Grimaldi MC, Milano G, Wadelius M, Glimelius B, Garmo H, Gusella M, Lecomte T, Laurent-Puig P, Martinez-Balibrea E, Sharma R, Garcia-Foncillas J, Kleibl Z, Morel A, Pignon JP, Midgley R, Kerr D, Tomlinson I (2014) Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol 32(10):1031–1039. doi:10.1200/jco.2013.51.1857 CrossRefPubMed

68.

Cao Z, Song J, Wang J, Guo X, Yu S, Dong W (2014) Association between polymorphisms in XRCC1 gene and treatment outcomes of patients with advanced gastric cancer: a systematic review and meta-analysis. PLoS ONE 9(1):e85357. doi:10.1371/journal.pone.0085357 CrossRefPubMedPubMedCentral

69.

Wang Z, Chen JQ, Liu JL, Qin XG, Huang Y (2012) Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review. BMC Gastroenterology 12:137. doi:10.1186/1471-230x-12-137 CrossRefPubMedPubMedCentral

70.

Ye F, Liu Z, Tan A, Liao M, Mo Z, Yang X (2013) XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis. Cancer Chemother Pharmacol 71(3):733–740. doi:10.1007/s00280-012-2067-8 CrossRefPubMed

71.

Peng Z, Wang Q, Gao J, Ji Z, Yuan J, Tian Y, Shen L (2013) Association between GSTP1 Ile105Val polymorphism and oxaliplatin-induced neuropathy: a systematic review and meta-analysis. Cancer Chemother Pharmacol 72(2):305–314. doi:10.1007/s00280-013-2194-x CrossRefPubMed

Titel: Predictive value of GSTP1 Ile105Val polymorphism in clinical outcomes of chemotherapy in gastric and colorectal cancers: a systematic review and meta-analysis
verfasst von: Xiaobing Shen
Jia Wang
Xiaoluan Yan
Xiaofeng Ren
Fan Wang
Xiaowei Chen
Yuchao Xu
Publikationsdatum: 06.05.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 6/2016
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-016-3047-1

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Predictive value of GSTP1 Ile105Val polymorphism in clinical outcomes of chemotherapy in gastric and colorectal cancers: a systematic review and meta-analysis

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2016

Evaluation of artemisinins for the treatment of acute myeloid leukemia

Phase II trial of concurrent bio-chemoradiotherapy using docetaxel, cisplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma

A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors

Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib

Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors

Platinum-based drugs: past, present and future

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie